The New American Addiction: How Weight-Loss Drugs Could Create the Next Epidemic

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) have rapidly gained popularity for obesity treatment, with unprecedented public enthusiasm and off-label use among otherwise healthy populations. While these agents demonstrate substantial weight-loss efficacy, emerging concerns highlight potential pharmaceutical dependency, ethical dilemmas, and long-term safety uncertainties. This article critically examines the mechanisms, benefits, and risks of GLP-1 agonists, emphasizing the need for regulatory oversight, psychological safeguards, and integration with lifestyle interventions. We propose a clinical framework in which GLP-1 agonists serve as a temporary adjunct, while structured exercise, dietary intervention, and behavioral therapy remain the standard of care for sustainable health.